## Luigi Atripaldi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6405652/publications.pdf

Version: 2024-02-01

933264 839398 34 442 10 18 citations g-index h-index papers 35 35 35 916 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine, 2020, 18, 405.	1.8	98
2	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy., 2020, 8, e001089.		72
3	Drug–Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection. Frontiers in Pharmacology, 2016, 7, 71.	1.6	31
4	Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. Gut, 2006, 55, 1370-1371.	6.1	27
5	Long-chain polyphosphates impair SARS-CoV-2 infection and replication. Science Signaling, 2021, 14, .	1.6	27
6	Impaired function of CD4+/CD25+ T regulatory lymphocytes characterizes the selfâ€limited hepatitis A virus infection. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e105-10.	1.4	19
7	Acute Rejection After Liver Transplantation: Is There a Specific Immunological Pattern?. Transplantation Proceedings, 2006, 38, 3594-3596.	0.3	16
8	Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scandinavian Journal of Gastroenterology, 2010, 45, 250-255.	0.6	13
9	No detection of SARS-CoV-2 in animals exposed to infected keepers: results ofÂa COVID-19 surveillance program. Future Science OA, 2021, 7, FSO711.	0.9	13
10	Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: Possible pathogenetic mechanisms. World Journal of Gastroenterology, 2006, 12, 1105.	1.4	13
11	Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania,) Tj ETQq1 1	0.784314	rgBŢ/Overl <mark>o</mark> c
12	Elevated CD4+/CD25+ T-cell Frequency and Function During Hepatitis C Virus Recurrence After Liver Transplantation. Transplantation Proceedings, 2009, 41, 1761-1766.	0.3	10
13	Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results. Frontiers in Pharmacology, 2017, 8, 797.	1.6	10
14	Effects of defibrillation shock in patients implanted with a subcutaneous defibrillator: a biomarker study. Europace, 2018, 20, f233-f239.	0.7	10
15	Prognostic value of pro-adrenomedullin and copeptin in acute infective endocarditis. BMC Infectious Diseases, 2021, 21, 23.	1.3	10
16	Interleukin-10 and tumor necrosis factor-alpha: model of immunomodulation in multiple sclerosis. Neurological Research, 2006, 28, 193-195.	0.6	9
17	Evidence of hepatitis C virus–specific interferon gamma–positive T cells in health care workers in an infectious disease department. American Journal of Infection Control, 2009, 37, 426-429.	1.1	8
18	Direct antiviral treatment of chronic hepatitis C in heart transplant recipients. Transplant Infectious Disease, 2018, 20, e12813.	0.7	6

#	Article	IF	CITATIONS
19	Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up. Frontiers in Public Health, 2021, 9, 801609.	1.3	5
20	CD4+/CD25+ T cells suppress autologous CD4+/CD25- lymphocytes and secrete granzyme B during acute and chronic hepatitis C. Pathogens and Disease, 2014, 72, n/a-n/a.	0.8	4
21	Lower CD4+ T-Cell Number Expressing CD7+ Characterizes HIV/Hepatitis C Virus Coinfection Compared With HIV and Hepatitis C Virus Monoinfection. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 504-506.	0.9	3
22	Increase of granzyme B-positive cells in ascitic fluid of patients with spontaneous bacterial peritonitis. Hepatology Research, 2008, 38, 410-414.	1.8	3
23	SERUM cardiacâ€specific biomarkers and atrial fibrillation in myotonic dystrophy type I. Journal of Cardiovascular Electrophysiology, 2019, 30, 2914-2919.	0.8	3
24	Utility of peripheral blood smear in rapid diagnosis of Pertussis. International Journal of Laboratory Hematology, 2019, 41, e41-e42.	0.7	3
25	Assessment of Saliva Specimens' Reliability for COVID-19 Surveillance. Frontiers in Public Health, 2022, 10, 840996.	1.3	3
26	HUMAN IMMUNODEFICIENCY VIRUS AND SUBTYPE 1B HEPATITIS C VIRUS: MORE SIMILARITIES THAN DIFFERENCES IN T-HELPER SUBSETS. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1310-1312.	1.4	2
27	Seroprevalence of SARS-CoV-2 Assessed by Four Chemiluminescence Immunoassays and One Immunocromatography Test for SARS-Cov-2. Frontiers in Public Health, 2021, 9, 649781.	1.3	2
28	An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2. Future Science OA, 2021, 7, FSO739.	0.9	2
29	Galectin-3 and Myocardial Fibrosis By Cardiac Magnetic Resonance in Thalassaemia Major. Blood, 2016, 128, 4832-4832.	0.6	2
30	Neonatal pertussis diagnosis: low procalcitonin level and high lymphocyte count are able to discriminate pertussis from bacterial and viral infections. New Microbiologica, 2019, 42, 49-51.	0.1	2
31	CD4+ T Lymphocytes and Cryoglobulins in Patients Coinfected with HIV and Hepatitis C Virus: Forgetting the Hidden CD4+ Cell Subsets. Clinical Infectious Diseases, 2005, 40, 1707-1708.	2.9	1
32	Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. Clinical Microbiology and Infection, 2010, 16, 676-678.	2.8	1
33	Evolution in Real-World Therapeutic Strategies for HIV Treatment: A Retrospective Study in Southern Italy, 2014–2020. Journal of Clinical Medicine, 2022, 11, 161.	1.0	1
34	Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19 Blood Transfusion, 2021, , .	0.3	0